Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Levonorgestrel-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Levonorgestrel |
Inferred relationship |
Some |
1 |
Ethinylestradiol 30 microgram and levonorgestrel 150 microgram oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 250 microgram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 250 microgram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Ethinylestradiol 20 microgram and levonorgestrel 100 microgram oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 50 microgram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 50 microgram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 125 microgram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Ethinylestradiol 20 microgram and levonorgestrel 90 microgram oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
2 |
Levonorgestrel 19.5 mg prolonged-release intrauterine drug delivery system |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
1 |
Levonorgestrel 19.5 mg prolonged-release intrauterine drug delivery system |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Levonorgestrel |
Inferred relationship |
Some |
1 |
Product containing precisely levonorgestrel 13.5 milligram/1 each prolonged-release intrauterine drug delivery system (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Levonorgestrel |
Inferred relationship |
Some |
1 |
Product containing precisely levonorgestrel 13.5 milligram/1 each prolonged-release intrauterine drug delivery system (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Levonorgestrel |
Inferred relationship |
Some |
1 |